Literature DB >> 25971649

Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Faryal Mirza1, Ernesto Canalis2.   

Abstract

Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures. Although idiopathic osteoporosis is the most common form of osteoporosis, secondary factors may contribute to the bone loss and increased fracture risk in patients presenting with fragility fractures or osteoporosis. Several medical conditions and medications significantly increase the risk for bone loss and skeletal fragility. This review focuses on some of the common causes of osteoporosis, addressing the underlying mechanisms, diagnostic approach and treatment of low bone mass in the presence of these conditions.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25971649      PMCID: PMC4534332          DOI: 10.1530/EJE-15-0118

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  262 in total

1.  Pathophysiology of bone loss in patients receiving anticonvulsant therapy.

Authors:  Lorraine A Fitzpatrick
Journal:  Epilepsy Behav       Date:  2004-02       Impact factor: 2.937

Review 2.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

3.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.

Authors:  K K Nicodemus; A R Folsom
Journal:  Diabetes Care       Date:  2001-07       Impact factor: 19.112

4.  Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis.

Authors:  M S Pearle; C G Roehrborn; C Y Pak
Journal:  J Endourol       Date:  1999-11       Impact factor: 2.942

Review 5.  Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment.

Authors:  Albert Parés; Núria Guañabens
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin.

Authors:  T C Dahlman
Journal:  Am J Obstet Gynecol       Date:  1993-04       Impact factor: 8.661

8.  The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance.

Authors:  Jessica Pepe; Maria Teresa Petrucci; Maria Lucia Mascia; Sara Piemonte; Valeria Fassino; Elisabetta Romagnoli; Salvatore Minisola
Journal:  Calcif Tissue Int       Date:  2008-06       Impact factor: 4.333

9.  Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.

Authors:  Ann E Kearns; Donald W Northfelt; Amylou C Dueck; Pamela J Atherton; Shaker R Dakhil; Kendrith M Rowland; Jyotsna Fuloria; Patrick J Flynn; Todor Dentchev; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2009-05-27       Impact factor: 3.603

10.  Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone.

Authors:  Melita M Dvorak; Cyrille De Joussineau; D Howard Carter; Trairak Pisitkun; Mark A Knepper; Gerardo Gamba; Paul J Kemp; Daniela Riccardi
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

View more
  61 in total

Review 1.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

2.  Systematic analysis of lncRNAs, mRNAs, circRNAs and miRNAs in patients with postmenopausal osteoporosis.

Authors:  Di Jin; Xiaowei Wu; Hongwen Yu; Lihong Jiang; Ping Zhou; Xiaoyi Yao; Jia Meng; Liping Wang; Meijie Zhang; Yina Zhang
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

3.  Surgery alters parameters of vitamin D status and other laboratory results.

Authors:  N Binkley; D Coursin; D Krueger; P Iglar; J Heiner; R Illgen; M Squire; J Lappe; P Watson; K Hogan
Journal:  Osteoporos Int       Date:  2016-11-08       Impact factor: 4.507

4.  Risk of osteoporosis and fracture in victims with burn injury.

Authors:  O Kaewboonchoo; F C Sung; C L Lin; H C Hsu; C T Kuo
Journal:  Osteoporos Int       Date:  2019-02-08       Impact factor: 4.507

5.  Descriptive study of mandibular canal visibility: morphometric and densitometric analysis for digital panoramic radiographs.

Authors:  Marius Kubilius; Ričardas Kubilius; Vaidas Varinauskas; Rimantas Žalinkevičius; Tolga F Tözüm; Gintaras Juodžbalys
Journal:  Dentomaxillofac Radiol       Date:  2016-05-31       Impact factor: 2.419

6.  Osteoporosis Management in Ankylosing Spondylitis.

Authors:  Alicia M Hinze; Grant H Louie
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-10-05

Review 7.  Regulation of Bone Metabolism by microRNAs.

Authors:  Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2018-02       Impact factor: 5.096

Review 8.  Impact of bone disease and pain in thalassemia.

Authors:  Antonio Piga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

9.  Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment.

Authors:  S Chiloiro; M Mormando; A Bianchi; A Giampietro; D Milardi; C Bima; G Grande; A M Formenti; G Mazziotti; A Pontecorvi; A Giustina; L De Marinis
Journal:  Endocrine       Date:  2017-08-23       Impact factor: 3.633

Review 10.  Bone quality changes associated with aging and disease: a review.

Authors:  Adele L Boskey; Laurianne Imbert
Journal:  Ann N Y Acad Sci       Date:  2017-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.